Progressive Supranuclear Palsy - A Pipeline Analysis Report
- Published: May 2018
- Pages: 72
- SKU: IRTNTR22822
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the drug development landscape for the development of drug for progressive supranuclear palsy including molecules at pre-clinical and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as indications coverage, therapies employed, preferred route of administration, therapeutic modality, and targets for drugs under development.
Overview of the drug development pipeline for progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a rare and progressive neurodegenerative disease, which is commonly known as Steele-Richardson-Olszewski syndrome. This condition is caused by the gradual damage of brain cells and the patients suffering from this condition undergo changes in personality, stiffness of muscles, dizziness, arthralgia, challenges with vision, speech, and facial movements, depression, and lack of interest. The prevalence of PSP is high among people above the age of 60. As a result, the growth of the global geriatric population will drive the demand for PSP treatments. Technavio’s market research analysts have predicted that with the introduction of medication, physiotherapy, speech therapy, and feeding tubes as some of the most promising investigational approaches to treat progressive supranuclear palsy, the global progressive supranuclear palsy market will witness growth in the forthcoming years.
According to progressive supranuclear palsy market overview, most of the drug development molecules in the pipeline are under the phase I and phase II development stages. For instance, sponsors such as Asceneuron developed ASN120290 and AbbVie developed ABBV-8E12, which are under phase I and phase II development stages respectively. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase II/III development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-clinical stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of progressive supranuclear palsy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
Therapeutic assessment of the drug development pipeline for progressive supranuclear palsy by preferred route of administration
The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.
Therapeutic assessment of the drug development pipeline for progressive supranuclear palsy by therapeutic modality
- Small molecule
- Monoclonal antibody
Based on the progressive supranuclear palsy market forecasts, the majority of molecules that are currently in the drug development pipeline for progressive supranuclear palsy are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for progressive supranuclear palsy?
- What are the companies that are currently involved in the development of drug molecules for progressive supranuclear palsy?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?